PL3363438T3 - Podstawione 2-azabicykle i ich zastosowanie w roli modulatorów receptora oreksynowego - Google Patents

Podstawione 2-azabicykle i ich zastosowanie w roli modulatorów receptora oreksynowego

Info

Publication number: PL3363438T3
Authority: PL; Poland
Prior art keywords: azabicycles; substituted; receptor modulators; orexin receptor; orexin
Prior art date: 2013-03-13

Application number

PL17206491T

Other languages

English (en)

Inventor

Christine F. GELIN

Terry P. LEBOLD

Brock T. Shireman

Jeannie M. ZIFF

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-13

Filing date

2014-03-12

Publication date

2020-02-28

2014-03-12 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2020-02-28 Publication of PL3363438T3 publication Critical patent/PL3363438T3/pl

Links

108050000742 Orexin Receptor Proteins 0.000 title 1
102000008834 Orexin receptor Human genes 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

PL17206491T 2013-03-13 2014-03-12 Podstawione 2-azabicykle i ich zastosowanie w roli modulatorów receptora oreksynowego PL3363438T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201361780378P	2013-03-13	2013-03-13
EP17206491.7A EP3363438B1 (en)	2013-03-13	2014-03-12	Substituted 2-azabicycles and their use as orexin receptor modulators
PCT/US2014/024293 WO2014165070A1 (en)	2013-03-13	2014-03-12	Substituted 2-azabicycles and their use as orexin receptor modulators
EP14717576.4A EP2970314B1 (en)	2013-03-13	2014-03-12	Substituted 2-azabicycles and their use as orexin receptor modulators

Publications (1)

Publication Number	Publication Date
PL3363438T3 true PL3363438T3 (pl)	2020-02-28

Family

ID=50487148

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL17206491T PL3363438T3 (pl)	2013-03-13	2014-03-12	Podstawione 2-azabicykle i ich zastosowanie w roli modulatorów receptora oreksynowego
PL19193122.9T PL3622956T3 (pl)	2013-03-13	2014-03-12	Podstawione 2-azabicykle i ich zastosowanie w roli modulatorów receptora oreksynowego
PL14717576T PL2970314T3 (pl)	2013-03-13	2014-03-12	Podstawione 2-azabicykle i ich zastosowanie w roli modulatorów receptora oreksynowego

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL19193122.9T PL3622956T3 (pl)	2013-03-13	2014-03-12	Podstawione 2-azabicykle i ich zastosowanie w roli modulatorów receptora oreksynowego
PL14717576T PL2970314T3 (pl)	2013-03-13	2014-03-12	Podstawione 2-azabicykle i ich zastosowanie w roli modulatorów receptora oreksynowego

Country Status (39)

Country	Link
US (5)	US8969352B2 (pl)
EP (4)	EP2970314B1 (pl)
JP (1)	JP6275815B2 (pl)
KR (1)	KR102209424B1 (pl)
CN (3)	CN110669052B (pl)
AR (1)	AR095423A1 (pl)
AU (2)	AU2014248680B2 (pl)
BR (1)	BR112015022294B1 (pl)
CA (1)	CA2904618C (pl)
CL (1)	CL2015002609A1 (pl)
CR (2)	CR20210523A (pl)
CY (3)	CY1120024T1 (pl)
DK (2)	DK2970314T3 (pl)
EA (1)	EA029276B1 (pl)
ES (3)	ES2659397T3 (pl)
HK (1)	HK1219725A1 (pl)
HR (3)	HRP20230633T1 (pl)
HU (3)	HUE063608T2 (pl)
IL (2)	IL240466B (pl)
JO (1)	JOP20140092B1 (pl)
LT (2)	LT2970314T (pl)
ME (2)	ME03011B (pl)
MX (2)	MX361529B (pl)
MY (1)	MY183725A (pl)
NI (1)	NI201500130A (pl)
NO (1)	NO3107630T3 (pl)
PE (1)	PE20151599A1 (pl)
PH (1)	PH12015501929B1 (pl)
PL (3)	PL3363438T3 (pl)
PT (2)	PT3363438T (pl)
RS (3)	RS64551B9 (pl)
SG (1)	SG11201507415QA (pl)
SI (2)	SI2970314T1 (pl)
SM (3)	SMT201900655T1 (pl)
TW (1)	TWI621618B (pl)
UA (1)	UA118669C2 (pl)
UY (1)	UY35409A (pl)
WO (1)	WO2014165070A1 (pl)
ZA (1)	ZA201507562B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2012004753A (es)	2009-10-23	2012-09-07	Janssen Pharmaceutica Nv	Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina.
AU2010343102B2 (en)	2009-12-29	2016-03-24	Dana-Farber Cancer Institute, Inc.	Type II Raf kinase inhibitors
EP2545964A1 (en)	2011-07-13	2013-01-16	Phenex Pharmaceuticals AG	Novel FXR (NR1H4) binding and activity modulating compounds
WO2013074986A1 (en)	2011-11-17	2013-05-23	Dana-Farber Cancer Institute, Inc.	Inhibitors of c-jun-n-terminal kinase (jnk)
TW201444849A (zh)	2013-03-13	2014-12-01	Janssen Pharmaceutica Nv	經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TW201444821A (zh)	2013-03-13	2014-12-01	Janssen Pharmaceutica Nv	經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TWI621618B (zh) *	2013-03-13	2018-04-21	比利時商健生藥品公司	經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
WO2015131773A1 (zh) *	2014-03-06	2015-09-11	上海海雁医药科技有限公司	作为食欲素受体拮抗剂的哌啶衍生物
MX2017003254A (es) *	2014-09-11	2017-10-12	Janssen Pharmaceutica Nv	2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
WO2016100157A2 (en) *	2014-12-19	2016-06-23	Merck Sharp & Dohme Corp.	6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
AU2015371251B2 (en)	2014-12-23	2020-06-11	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2017012502A1 (en)	2015-07-17	2017-01-26	Sunshine Lake Pharma Co., Ltd.	Substituted quinazoline compounds and preparation and uses thereof
EP3336088B1 (en)	2015-08-14	2021-04-21	Shanghai Haiyan Pharmaceutical Technology Co., Ltd.	Crystal form of orexin receptor antagonist compound, and preparation method and application thereof
EP3347018B1 (en)	2015-09-09	2021-09-01	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
CN106749269B (zh)	2015-11-23	2019-01-04	广东东阳光药业有限公司	八氢吡咯并[3,4-c]吡咯衍生物及其用途
PL3426251T3 (pl)	2016-03-10	2022-07-18	Janssen Pharmaceutica Nv	Sposoby leczenia depresji za pomocą antagonistów receptora typu 2 oreksyny
KR102269305B1 (ko)	2016-06-13	2021-06-25	길리애드 사이언시즈, 인코포레이티드	Fxr (nr1h4) 조정 화합물
CA2968836A1 (en)	2016-06-13	2017-12-13	Gilead Sciences, Inc.	Fxr (nr1h4) modulating compounds
WO2018098361A1 (en)	2016-11-22	2018-05-31	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 12 (cdk12) and uses thereof
KR20220119520A (ko)	2017-03-28	2022-08-29	길리애드 사이언시즈, 인코포레이티드	간 질환을 치료하기 위한 치료 조합물
GB2558975B (en) *	2017-09-01	2019-01-23	Chronos Therapeutics Ltd	Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
EP3676261B1 (en)	2017-09-01	2024-12-18	Chronos Therapeutics Limited	Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
CN112367991A (zh)	2018-06-25	2021-02-12	达纳-法伯癌症研究所股份有限公司	Taire家族激酶抑制剂及其用途
US20220073512A1 (en) *	2018-12-14	2022-03-10	Dana-Farber Cancer Institute, Inc.	Pyrazolopyridine inhibitors of c-jun-n-terminal kinases and uses thereof
HUE065889T2 (hu)	2019-01-15	2024-06-28	Gilead Sciences Inc	Izoxazol vegyület mint FXR agonista és az azt tartalmazó gyógyszerészeti készítmények
CN118388474A (zh)	2019-02-19	2024-07-26	吉利德科学公司	Fxr激动剂的固体形式

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3674793A (en)	1967-03-29	1972-07-04	Sterling Drug Inc	6-hydroxy-2-azabicyclo(2.2.2)octan-3-ones and 2-azabicyclo(2.2.2.)octane-3,6-diones
US6505492B2 (en)	2001-04-11	2003-01-14	Bethlehem Steel Corporation	Method and apparatus for forming deep-drawn articles
JPWO2002094790A1 (ja)	2001-05-23	2004-09-09	三菱ウェルファーマ株式会社	縮合ヘテロ環化合物およびその医薬用途
WO2004069816A1 (en)	2003-02-07	2004-08-19	Ranbaxy Laboratories Limited	Oxazolidinone derivatives as antimicrobials
CA2516329A1 (en)	2003-02-21	2004-09-02	Pharmacia & Upjohn Company Llc	Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them
WO2007071358A1 (en)	2005-12-20	2007-06-28	Novartis Ag	Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
JP2010502664A (ja)	2006-09-11	2010-01-28	ノバルティスアクチエンゲゼルシャフト	代謝型グルタミン酸受容体の調節剤としてのニコチン酸誘導体
US8133901B2 (en)	2006-12-01	2012-03-13	Actelion Pharmaceuticals Ltd.	3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors
CL2007003827A1 (es)	2006-12-28	2008-09-26	Actelion Pharmaceuticals Ltd	Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
WO2008150364A1 (en) *	2007-05-23	2008-12-11	Merck & Co., Inc.	Cyclopropyl pyrrolidine orexin receptor antagonists
TW200904439A (en)	2007-07-17	2009-02-01	Bristol Myers Squibb Co	Pyridone GPR119 G protein-coupled receptor agonists
BRPI0821141A2 (pt)	2007-12-21	2015-06-16	Hoffmann La Roche	Derivados de heteroarila como antagonistas do receptor de orexina
CA2713184A1 (en) *	2008-02-21	2009-08-27	Actelion Pharmaceuticals Ltd	2-aza-bicyclo[2.2.1]heptane derivatives
WO2009133522A1 (en)	2008-04-30	2009-11-05	Actelion Pharmaceuticals Ltd	Piperidine and pyrrolidine compounds
EP2318404B1 (en)	2008-07-16	2013-08-21	Merck Sharp & Dohme Corp.	Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
US8710076B2 (en)	2008-10-21	2014-04-29	Merck Sharp & Dohme Corp.	2,5-disubstituted piperidine orexin receptor antagonists
JP2012506378A (ja)	2008-10-21	2012-03-15	メルク・シャープ・エンド・ドーム・コーポレイション	２，３−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト
TW201033190A (en)	2008-12-02	2010-09-16	Glaxo Group Ltd	Novel compounds
AR076024A1 (es)	2009-04-03	2011-05-11	Schering Corp	Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
EA201171293A1 (ru)	2009-04-24	2012-05-30	Глэксо Груп Лимитед	3-азабицикло[4.1.0]гептаны, применяемые в качестве антагонистов орексина
JP5847087B2 (ja) *	2009-10-23	2016-01-20	ヤンセンファーマシューティカエヌ．ベー．	オレキシン受容体調節因子としての縮合複素環式化合物
US9062044B2 (en)	2009-10-23	2015-06-23	Janssen Pharmaceutica Nv	Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
MX2012004753A (es)	2009-10-23	2012-09-07	Janssen Pharmaceutica Nv	Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina.
CA2778684A1 (en)	2009-10-29	2011-05-05	Schering Corporation	Bridged bicyclic piperidine derivatives and methods of use thereof
US9301929B2 (en)	2009-11-24	2016-04-05	Merck Sharp & Dohme Corp.	Substituted biaryl derivatives and methods of use thereof
EP2512239A4 (en)	2009-12-14	2014-11-26	Inspire Pharmaceuticals Inc	BROKEN BICYCLIC RHO-KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE
US8697691B2 (en)	2009-12-21	2014-04-15	Vanderbilt University	Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same
UY33227A (es)	2010-02-19	2011-09-30	Novartis Ag	Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011159657A1 (en)	2010-06-18	2011-12-22	Merck Sharp & Dohme Corp.	Bicyclic heterocycle derivatives and methods of use thereof
WO2012089606A1 (en)	2010-12-28	2012-07-05	Glaxo Group Limited	Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
US9586962B2 (en)	2011-04-20	2017-03-07	Janssen Pharmaceutica Nv	Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2014066196A1 (en)	2012-10-23	2014-05-01	Merck Sharp & Dohme Corp.	2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists
MX2015006191A (es)	2012-11-16	2015-08-10	Merck Sharp & Dohme	Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana.
TWI621618B (zh) *	2013-03-13	2018-04-21	比利時商健生藥品公司	經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh)	2013-03-13	2014-12-01	Janssen Pharmaceutica Nv	經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
AU2015214366B2 (en)	2014-02-06	2019-04-18	Abbvie, Inc.	6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
MX2017003254A (es)	2014-09-11	2017-10-12	Janssen Pharmaceutica Nv	2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.

2014
- 2014-03-11 TW TW103108293A patent/TWI621618B/zh active
- 2014-03-12 ME MEP-2018-46A patent/ME03011B/me unknown
- 2014-03-12 SI SI201430542T patent/SI2970314T1/en unknown
- 2014-03-12 RS RS20230703A patent/RS64551B9/sr unknown
- 2014-03-12 RS RS20180158A patent/RS56875B1/sr unknown
- 2014-03-12 AU AU2014248680A patent/AU2014248680B2/en active Active
- 2014-03-12 CR CR20210523A patent/CR20210523A/es unknown
- 2014-03-12 JP JP2016501487A patent/JP6275815B2/ja active Active
- 2014-03-12 EP EP14717576.4A patent/EP2970314B1/en active Active
- 2014-03-12 SG SG11201507415QA patent/SG11201507415QA/en unknown
- 2014-03-12 ES ES14717576.4T patent/ES2659397T3/es active Active
- 2014-03-12 JO JOP/2014/0092A patent/JOP20140092B1/ar active
- 2014-03-12 EP EP23176328.5A patent/EP4272824A3/en not_active Withdrawn
- 2014-03-12 ME MEP-2019-314A patent/ME03572B/me unknown
- 2014-03-12 MX MX2015011815A patent/MX361529B/es active IP Right Grant
- 2014-03-12 SI SI201431351T patent/SI3363438T1/sl unknown
- 2014-03-12 RS RSP20191419 patent/RS59466B1/sr unknown
- 2014-03-12 EP EP19193122.9A patent/EP3622956B9/en active Active
- 2014-03-12 PL PL17206491T patent/PL3363438T3/pl unknown
- 2014-03-12 EA EA201591703A patent/EA029276B1/ru unknown
- 2014-03-12 US US14/206,722 patent/US8969352B2/en active Active
- 2014-03-12 LT LTEP14717576.4T patent/LT2970314T/lt unknown
- 2014-03-12 UA UAA201509932A patent/UA118669C2/uk unknown
- 2014-03-12 SM SM20190655T patent/SMT201900655T1/it unknown
- 2014-03-12 CN CN201910948604.1A patent/CN110669052B/zh active Active
- 2014-03-12 PE PE2015001954A patent/PE20151599A1/es active IP Right Grant
- 2014-03-12 LT LT17206491T patent/LT3363438T/lt unknown
- 2014-03-12 WO PCT/US2014/024293 patent/WO2014165070A1/en active Application Filing
- 2014-03-12 PL PL19193122.9T patent/PL3622956T3/pl unknown
- 2014-03-12 HU HUE19193122A patent/HUE063608T2/hu unknown
- 2014-03-12 CA CA2904618A patent/CA2904618C/en active Active
- 2014-03-12 SM SM20230223T patent/SMT202300223T1/it unknown
- 2014-03-12 DK DK14717576.4T patent/DK2970314T3/en active
- 2014-03-12 MX MX2018015165A patent/MX368466B/es unknown
- 2014-03-12 MY MYPI2015703021A patent/MY183725A/en unknown
- 2014-03-12 HR HRP20230633TT patent/HRP20230633T1/hr unknown
- 2014-03-12 HU HUE17206491A patent/HUE047592T2/hu unknown
- 2014-03-12 ES ES19193122T patent/ES2950032T3/es active Active
- 2014-03-12 US US14/774,555 patent/US9611277B2/en active Active
- 2014-03-12 HU HUE14717576A patent/HUE036193T2/hu unknown
- 2014-03-12 EP EP17206491.7A patent/EP3363438B1/en active Active
- 2014-03-12 CN CN201480027437.2A patent/CN105308048B/zh active Active
- 2014-03-12 SM SM20180056T patent/SMT201800056T1/it unknown
- 2014-03-12 PT PT172064917T patent/PT3363438T/pt unknown
- 2014-03-12 PL PL14717576T patent/PL2970314T3/pl unknown
- 2014-03-12 DK DK17206491T patent/DK3363438T3/da active
- 2014-03-12 PT PT147175764T patent/PT2970314T/pt unknown
- 2014-03-12 ES ES17206491T patent/ES2760564T3/es active Active
- 2014-03-12 BR BR112015022294-3A patent/BR112015022294B1/pt active IP Right Grant
- 2014-03-12 CN CN201810842686.7A patent/CN108864093A/zh active Pending
- 2014-03-12 KR KR1020157028720A patent/KR102209424B1/ko active Active
- 2014-03-13 UY UY0001035409A patent/UY35409A/es not_active Application Discontinuation
- 2014-03-13 AR ARP140100967A patent/AR095423A1/es active IP Right Grant
- 2014-11-19 NO NO14808529A patent/NO3107630T3/no unknown
2015
- 2015-01-26 US US14/605,387 patent/US9447117B2/en active Active
- 2015-08-10 IL IL240466A patent/IL240466B/en active IP Right Grant
- 2015-08-24 CR CR20150433A patent/CR20150433A/es unknown
- 2015-09-02 PH PH12015501929A patent/PH12015501929B1/en unknown
- 2015-09-10 NI NI201500130A patent/NI201500130A/es unknown
- 2015-09-11 CL CL2015002609A patent/CL2015002609A1/es unknown
- 2015-10-12 ZA ZA2015/07562A patent/ZA201507562B/en unknown
2016
- 2016-06-30 HK HK16107630.3A patent/HK1219725A1/zh unknown
- 2016-08-26 US US15/248,945 patent/US9845333B2/en active Active
2017
- 2017-04-04 US US15/478,888 patent/US10183953B2/en active Active
2018
- 2018-02-20 HR HRP20180303TT patent/HRP20180303T1/hr unknown
- 2018-03-09 CY CY20181100284T patent/CY1120024T1/el unknown
- 2018-07-03 AU AU2018204835A patent/AU2018204835B2/en active Active
2019
- 2019-02-03 IL IL264606A patent/IL264606A/en unknown
- 2019-11-08 HR HRP20192032TT patent/HRP20192032T1/hr unknown
- 2019-12-02 CY CY20191101261T patent/CY1122392T1/el unknown
2023
- 2023-07-25 CY CY20231100361T patent/CY1126106T1/el unknown

Also Published As

Publication number	Publication date
DK2970314T3 (en)	2018-02-26
ES2760564T3 (es)	2020-05-14
TW201446757A (zh)	2014-12-16
US20160052939A1 (en)	2016-02-25
WO2014165070A1 (en)	2014-10-09
SMT201900655T1 (it)	2020-01-14
US20140275118A1 (en)	2014-09-18
RS64551B1 (sr)	2023-10-31
SMT202300223T1 (it)	2023-09-06
CN110669052B (zh)	2022-10-11
KR20150126694A (ko)	2015-11-12
PL2970314T3 (pl)	2018-05-30
EP4272824A2 (en)	2023-11-08
EP3622956A1 (en)	2020-03-18
US10183953B2 (en)	2019-01-22
EP3622956B9 (en)	2023-09-27
UY35409A (es)	2014-09-30
EP3622956B1 (en)	2023-06-07
LT2970314T (lt)	2018-02-12
US20170015651A1 (en)	2017-01-19
CN105308048B (zh)	2019-10-08
PT2970314T (pt)	2018-03-05
DK3363438T3 (da)	2019-11-11
US9611277B2 (en)	2017-04-04
AR095423A1 (es)	2015-10-14
ES2659397T3 (es)	2018-03-15
PT3363438T (pt)	2019-12-11
CY1122392T1 (el)	2021-01-27
JOP20140092B1 (ar)	2021-08-17
CN110669052A (zh)	2020-01-10
RS59466B1 (sr)	2019-11-29
CR20210523A (es)	2021-11-19
MX2015011815A (es)	2016-11-07
KR102209424B1 (ko)	2021-01-29
EA029276B1 (ru)	2018-03-30
US8969352B2 (en)	2015-03-03
ES2950032T3 (es)	2023-10-04
EP2970314B1 (en)	2017-12-13
CY1126106T1 (el)	2023-11-15
HRP20192032T1 (hr)	2020-02-07
US20150174129A1 (en)	2015-06-25
IL240466A0 (en)	2015-09-24
UA118669C2 (uk)	2019-02-25
CY1120024T1 (el)	2018-12-12
HK1219725A1 (zh)	2017-04-13
MX368466B (es)	2019-10-03
JP2016512535A (ja)	2016-04-28
AU2014248680B2 (en)	2018-07-26
LT3363438T (lt)	2019-11-11
HUE047592T2 (hu)	2020-05-28
ZA201507562B (en)	2019-04-24
HRP20230633T1 (hr)	2023-09-29
CL2015002609A1 (es)	2016-03-28
NI201500130A (es)	2015-11-30
RS56875B1 (sr)	2018-04-30
SI3363438T1 (sl)	2019-11-29
US9845333B2 (en)	2017-12-19
US9447117B2 (en)	2016-09-20
MX361529B (es)	2018-12-07
ME03011B (me)	2018-10-20
SG11201507415QA (en)	2015-10-29
HUE036193T2 (hu)	2018-06-28
EP4272824A3 (en)	2024-01-10
IL240466B (en)	2019-03-31
PL3622956T3 (pl)	2023-09-18
ME03572B (me)	2020-07-20
NO3107630T3 (pl)	2018-01-06
AU2018204835A1 (en)	2018-07-19
EP3363438A1 (en)	2018-08-22
PH12015501929A1 (en)	2016-01-04
CA2904618C (en)	2021-12-07
US20170204096A1 (en)	2017-07-20
SI2970314T1 (en)	2018-02-28
CN108864093A (zh)	2018-11-23
TWI621618B (zh)	2018-04-21
BR112015022294A2 (pt)	2017-07-18
CN105308048A (zh)	2016-02-03
PE20151599A1 (es)	2015-11-12
EP3622956C0 (en)	2023-06-07
EP3363438B1 (en)	2019-09-18
CR20150433A (es)	2015-10-26
SMT201800056T1 (it)	2018-03-08
HRP20180303T1 (hr)	2018-03-23
BR112015022294B1 (pt)	2022-09-13
PH12015501929B1 (en)	2016-01-04
IL264606A (en)	2019-02-28
AU2018204835B2 (en)	2019-08-08
JP6275815B2 (ja)	2018-02-07
MY183725A (en)	2021-03-10
EA201591703A1 (ru)	2016-02-29
EP2970314A1 (en)	2016-01-20
AU2014248680A1 (en)	2015-08-27
NZ710872A (en)	2020-10-30
CA2904618A1 (en)	2014-10-09
RS64551B9 (sr)	2023-12-29
HUE063608T2 (hu)	2024-01-28

Publication	Publication Date	Title
IL264606A (en)	2019-02-28	2- Converted azabicycles and their use as orexin receptor modulators
HK1219726A1 (zh)	2017-04-13	取代的 -氮雜二環化合物以及它們作為食欲素受體調節劑的用途
IL245733A0 (en)	2016-07-31	aplnr modulators and their uses
HK1218417A1 (zh)	2017-02-17	螺-內酰胺受體調節劑及其用途
HK1218418A1 (zh)	2017-02-17	螺-內酰胺受體調節劑及其用途
HK1203493A1 (en)	2015-10-30	Substituted azabicycles and use thereof
ZA201800827B (en)	2019-09-25	Substituted 4-azaindoles and their use as glun2b receptor modulators
GB201305277D0 (en)	2013-05-01	Novel combination and use
HK1203198A1 (en)	2015-10-23	Substituted phenylimidazopyrazoles and use thereof
GB201307989D0 (en)	2013-06-12	Novel combinations and use
EP3013851A4 (en)	2016-12-28	MODULATORS OF BRADYKININ RECEPTORS AND THEIR USE